Peter Radovich, who serves as President and Chief Operating Officer of Mirum Pharmaceuticals, sold 16,515 shares of the company's common stock on March 16, 2026. The shares were disposed of at a per-share price of $91.9779, producing proceeds of approximately $1.5 million.
The disposal followed an option exercise on March 15, 2026, when Radovich exercised rights to acquire a total of 30,220 shares of Mirum common stock. Those option-related transactions were tied to Performance Restricted Stock Units - each unit representing a contingent entitlement to one share of common stock.
Since the sale, Mirum's share price has moved higher, reaching $96.60. That level represents a 114% increase in the stock over the prior 12 months.
On the operational front, Mirum reported fourth-quarter 2025 results that included $360 million in sales of LIVMARLI, of which $245 million were generated in the United States. The company said those Livmarli revenues represented 69% year-over-year growth for the quarter.
Mirum reiterated its fiscal 2026 product sales guidance, maintaining a range of $630 million to $650 million. The company also reported progress across its late-stage clinical programs: it completed enrollment in the Phase 3 EXPAND study evaluating LIVMARLI for cholestatic pruritus in patients with rare liver diseases, an effort intended to explore uses beyond Alagille syndrome and PFIC. Additionally, Mirum completed enrollment in the Phase 3 AZURE 1 study and finished screening for the AZURE 4 study, both assessing treatments for chronic hepatitis delta virus infection.
Market commentary and analyst reactions have varied. An InvestingPro analysis flagged Mirum - with an implied market value of $5.8 billion - as appearing overvalued at current levels and noted the company is not yet profitable. Independent analyst firms have issued a range of price targets and ratings: Citizens left its Market Outperform rating and a $132 price objective intact; Morgan Stanley reiterated an Overweight rating with a $130 target; Evercore ISI raised its target to $126, citing pipeline progress; and Leerink Partners trimmed its target slightly to $118 while maintaining an Outperform rating.
These developments - insider transactions, firm financial guidance, clinical trial milestones, and divergent analyst assessments - frame the current market narrative around Mirum Pharmaceuticals as it advances commercial and clinical objectives amid differing views on valuation and profitability.